Doximity, Inc. · Healthcare
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 36.0% margin the price requires 10.7% 3y revenue CAGR against 6.7% consensus, a cushion of -9.6pt versus a 0pt correction cut. Price needs more growth than consensus at any nearby discount rate, so the correction has room to go further. AI-flavored multiple, but revenue is pharma ad budgets; cut the multiple, not the growth.
Would recover if: the FY2027 4% subscription guide and share-loss lawsuits prove right. We re-check this against analyst estimates every evening.
10 years, at a 36% margin (analysts' margin, cut for cash conversion)
+5.0%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
6 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 95% of reported profit arrived as operating cash, so the test cuts the analysts' 41% margin to 39%. That leaves a cushion of −8pt instead of −7pt, and the smaller of the two decides the group.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 23, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 17th percentile of published models, 19% below the median target, meaning the market has heard the bull case for AI and rejected it, choosing instead to price a steep deceleration from recent growth.
Whether Doximity's AI tools are actually capturing new pharmaceutical budgets and reversing the market-share losses alleged in the lawsuits — and the wired data on unit volumes can only confirm the deceleration the price already assumes, not settle the AI monetization question.
What the price refuses to pay for, and the full reconstruction, on the DOCS quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names